NO322632B1 - Anvendelse av et antistoff for fremstilling av et medikament til behandling av benmetabolismeunormalitet. - Google Patents
Anvendelse av et antistoff for fremstilling av et medikament til behandling av benmetabolismeunormalitet. Download PDFInfo
- Publication number
- NO322632B1 NO322632B1 NO19985848A NO985848A NO322632B1 NO 322632 B1 NO322632 B1 NO 322632B1 NO 19985848 A NO19985848 A NO 19985848A NO 985848 A NO985848 A NO 985848A NO 322632 B1 NO322632 B1 NO 322632B1
- Authority
- NO
- Norway
- Prior art keywords
- obm
- ocif
- protein
- cells
- human
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 19
- 230000004097 bone metabolism Effects 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title claims description 20
- 230000005856 abnormality Effects 0.000 title claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 341
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 336
- 108010035042 Osteoprotegerin Proteins 0.000 claims abstract description 324
- 102000008108 Osteoprotegerin Human genes 0.000 claims abstract description 324
- 230000004071 biological effect Effects 0.000 claims abstract description 43
- 210000002997 osteoclast Anatomy 0.000 claims description 95
- 230000000694 effects Effects 0.000 claims description 76
- 230000001582 osteoblastic effect Effects 0.000 claims description 39
- 210000002536 stromal cell Anatomy 0.000 claims description 39
- 210000004989 spleen cell Anatomy 0.000 claims description 34
- 230000004069 differentiation Effects 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 29
- 208000006386 Bone Resorption Diseases 0.000 claims description 28
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 28
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 28
- 230000024279 bone resorption Effects 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 28
- 229960001319 parathyroid hormone Drugs 0.000 claims description 28
- 239000000199 parathyroid hormone Substances 0.000 claims description 28
- 230000035800 maturation Effects 0.000 claims description 26
- 238000003501 co-culture Methods 0.000 claims description 19
- 238000010494 dissociation reaction Methods 0.000 claims description 16
- 230000005593 dissociations Effects 0.000 claims description 16
- 210000000170 cell membrane Anatomy 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 2
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 230000000148 hypercalcaemia Effects 0.000 claims description 2
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000006409 renal osteodystrophy Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 152
- 230000027455 binding Effects 0.000 abstract description 94
- 238000009739 binding Methods 0.000 abstract description 93
- 230000014509 gene expression Effects 0.000 abstract description 61
- 238000012216 screening Methods 0.000 abstract description 57
- 239000000126 substance Substances 0.000 abstract description 36
- 102000005962 receptors Human genes 0.000 abstract description 17
- 108020003175 receptors Proteins 0.000 abstract description 17
- 238000010353 genetic engineering Methods 0.000 abstract description 12
- 230000009471 action Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 310
- 210000004027 cell Anatomy 0.000 description 308
- 239000002299 complementary DNA Substances 0.000 description 152
- 241000699666 Mus <mouse, genus> Species 0.000 description 148
- 239000000243 solution Substances 0.000 description 141
- 239000002953 phosphate buffered saline Substances 0.000 description 103
- 108020004414 DNA Proteins 0.000 description 98
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 90
- 239000012634 fragment Substances 0.000 description 81
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 79
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 53
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 51
- 235000005282 vitamin D3 Nutrition 0.000 description 51
- 239000011647 vitamin D3 Substances 0.000 description 51
- 229940021056 vitamin d3 Drugs 0.000 description 51
- 230000015572 biosynthetic process Effects 0.000 description 49
- 239000012528 membrane Substances 0.000 description 49
- 239000000203 mixture Substances 0.000 description 47
- 239000013612 plasmid Substances 0.000 description 46
- 239000001963 growth medium Substances 0.000 description 45
- 239000011780 sodium chloride Substances 0.000 description 45
- 239000000872 buffer Substances 0.000 description 44
- 210000004379 membrane Anatomy 0.000 description 44
- 238000000746 purification Methods 0.000 description 41
- 241000588724 Escherichia coli Species 0.000 description 39
- 210000004408 hybridoma Anatomy 0.000 description 37
- 241000283973 Oryctolagus cuniculus Species 0.000 description 36
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 35
- 238000002835 absorbance Methods 0.000 description 33
- 102000036639 antigens Human genes 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 108091008146 restriction endonucleases Proteins 0.000 description 30
- 239000000427 antigen Substances 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 28
- 229960003957 dexamethasone Drugs 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 28
- 150000001413 amino acids Chemical group 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000003636 conditioned culture medium Substances 0.000 description 26
- 238000007796 conventional method Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 239000013604 expression vector Substances 0.000 description 23
- 230000002159 abnormal effect Effects 0.000 description 22
- 239000012091 fetal bovine serum Substances 0.000 description 22
- 238000002372 labelling Methods 0.000 description 22
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 21
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 21
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 21
- 229920000053 polysorbate 80 Polymers 0.000 description 21
- 229940068968 polysorbate 80 Drugs 0.000 description 21
- 238000005406 washing Methods 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 20
- 239000000499 gel Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 102000014914 Carrier Proteins Human genes 0.000 description 19
- 210000004102 animal cell Anatomy 0.000 description 19
- 108091008324 binding proteins Proteins 0.000 description 19
- 239000000178 monomer Substances 0.000 description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 18
- 239000012228 culture supernatant Substances 0.000 description 17
- 238000011534 incubation Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229920002684 Sepharose Polymers 0.000 description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 229960000723 ampicillin Drugs 0.000 description 16
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 16
- 238000001962 electrophoresis Methods 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 239000000825 pharmaceutical preparation Substances 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102000013415 peroxidase activity proteins Human genes 0.000 description 15
- 108040007629 peroxidase activity proteins Proteins 0.000 description 15
- 238000002965 ELISA Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 230000003053 immunization Effects 0.000 description 14
- 238000003752 polymerase chain reaction Methods 0.000 description 14
- 230000009870 specific binding Effects 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 102000037865 fusion proteins Human genes 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 12
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 12
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 102000013563 Acid Phosphatase Human genes 0.000 description 12
- 108010051457 Acid Phosphatase Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 229920001213 Polysorbate 20 Polymers 0.000 description 12
- 229940098773 bovine serum albumin Drugs 0.000 description 12
- 238000004132 cross linking Methods 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 244000005700 microbiome Species 0.000 description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 12
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 11
- 238000012258 culturing Methods 0.000 description 11
- 229960002897 heparin Drugs 0.000 description 11
- 229920000669 heparin Polymers 0.000 description 11
- 238000002649 immunization Methods 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 229940068977 polysorbate 20 Drugs 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 238000000246 agarose gel electrophoresis Methods 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000001509 sodium citrate Substances 0.000 description 10
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 108060008226 thioredoxin Proteins 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000001143 conditioned effect Effects 0.000 description 9
- 238000001641 gel filtration chromatography Methods 0.000 description 9
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 9
- 108010052968 leupeptin Proteins 0.000 description 9
- 229920002401 polyacrylamide Polymers 0.000 description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 238000000159 protein binding assay Methods 0.000 description 9
- 238000003118 sandwich ELISA Methods 0.000 description 9
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 8
- 239000013504 Triton X-100 Substances 0.000 description 8
- 229920004890 Triton X-100 Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 244000309466 calf Species 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 230000009871 nonspecific binding Effects 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 102000002933 Thioredoxin Human genes 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000012064 sodium phosphate buffer Substances 0.000 description 7
- 229940094937 thioredoxin Drugs 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010039627 Aprotinin Proteins 0.000 description 6
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 6
- 239000007836 KH2PO4 Substances 0.000 description 6
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229960004405 aprotinin Drugs 0.000 description 6
- 239000007795 chemical reaction product Substances 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 238000007865 diluting Methods 0.000 description 6
- 239000013024 dilution buffer Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 238000006911 enzymatic reaction Methods 0.000 description 6
- 230000001747 exhibiting effect Effects 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 6
- 239000007973 glycine-HCl buffer Substances 0.000 description 6
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 230000003642 osteotropic effect Effects 0.000 description 6
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 235000002906 tartaric acid Nutrition 0.000 description 6
- 239000011975 tartaric acid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000004677 Nylon Substances 0.000 description 5
- 108010067902 Peptide Library Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000006172 buffering agent Substances 0.000 description 5
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 5
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 5
- 235000020964 calcitriol Nutrition 0.000 description 5
- 239000011612 calcitriol Substances 0.000 description 5
- 229960005084 calcitriol Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 5
- 238000001400 expression cloning Methods 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 108010091212 pepstatin Proteins 0.000 description 5
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000011535 reaction buffer Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 102000003951 Erythropoietin Human genes 0.000 description 4
- 108090000394 Erythropoietin Proteins 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- -1 bisphosphonate compounds Chemical class 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940105423 erythropoietin Drugs 0.000 description 4
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108010087765 Antipain Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 229920001342 Bakelite® Polymers 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000003815 Interleukin-11 Human genes 0.000 description 3
- 108090000177 Interleukin-11 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 3
- 101100261207 Mus musculus Tnfrsf11b gene Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000003431 cross linking reagent Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229950000964 pepstatin Drugs 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- 108010001789 Calcitonin Receptors Proteins 0.000 description 2
- 102100038520 Calcitonin receptor Human genes 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108090000630 Oncostatin M Proteins 0.000 description 2
- 102000004140 Oncostatin M Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100036407 Thioredoxin Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960003669 carbenicillin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 239000011544 gradient gel Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010068072 salmon calcitonin Proteins 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- PMHUSCHKTSTQEP-UHFFFAOYSA-N (4-carbamimidoylphenyl)methanesulfonyl fluoride Chemical compound NC(=N)C1=CC=C(CS(F)(=O)=O)C=C1 PMHUSCHKTSTQEP-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022337 Integrin alpha-V Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- SFBODOKJTYAUCM-UHFFFAOYSA-N Ipriflavone Chemical compound C=1C(OC(C)C)=CC=C(C2=O)C=1OC=C2C1=CC=CC=C1 SFBODOKJTYAUCM-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101100018717 Mus musculus Il1rl1 gene Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 108010048673 Vitronectin Receptors Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 108010009896 bone resorption factor Proteins 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960005431 ipriflavone Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9780897 | 1997-04-15 | ||
| JP15143497 | 1997-06-09 | ||
| JP21789797 | 1997-08-12 | ||
| JP22480397 | 1997-08-21 | ||
| JP33224197 | 1997-12-02 | ||
| PCT/JP1998/001728 WO1998046644A1 (fr) | 1997-04-15 | 1998-04-15 | Nouvelle proteine et methode de production associee |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO985848D0 NO985848D0 (no) | 1998-12-14 |
| NO985848L NO985848L (no) | 1999-02-15 |
| NO322632B1 true NO322632B1 (no) | 2006-11-06 |
Family
ID=27525882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19985848A NO322632B1 (no) | 1997-04-15 | 1998-12-14 | Anvendelse av et antistoff for fremstilling av et medikament til behandling av benmetabolismeunormalitet. |
| NO2010021C NO2010021I2 (no) | 1997-04-15 | 2010-11-25 | Denosumab |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2010021C NO2010021I2 (no) | 1997-04-15 | 2010-11-25 | Denosumab |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US7527790B2 (fr) |
| EP (3) | EP0911342B2 (fr) |
| JP (7) | JP3523650B2 (fr) |
| KR (1) | KR100496063B1 (fr) |
| CN (1) | CN1138786C (fr) |
| AT (1) | ATE328006T1 (fr) |
| AU (1) | AU735355B2 (fr) |
| CA (2) | CA2257247C (fr) |
| CY (1) | CY2010017I2 (fr) |
| DE (2) | DE122010000049I1 (fr) |
| DK (1) | DK0911342T4 (fr) |
| ES (1) | ES2263204T5 (fr) |
| FR (1) | FR10C0048I2 (fr) |
| HU (3) | HU229841B1 (fr) |
| IL (1) | IL127115A (fr) |
| LU (1) | LU91759I2 (fr) |
| NO (2) | NO322632B1 (fr) |
| NZ (1) | NZ332995A (fr) |
| PT (1) | PT911342E (fr) |
| RU (1) | RU2238949C2 (fr) |
| WO (1) | WO1998046644A1 (fr) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US7632922B1 (en) * | 1995-12-22 | 2009-12-15 | Amgen, Inc. | Osteoprotegerin |
| US20050147611A1 (en) * | 1995-12-22 | 2005-07-07 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
| EP1995318A1 (fr) | 1996-12-13 | 2008-11-26 | Schering Corporation | Antigènes de surface de cellule de mammifère ; agents chimiques relatifs |
| JP2002509431A (ja) * | 1996-12-23 | 2002-03-26 | イミュネックス・コーポレーション | ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である− |
| US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| RU2238949C2 (ru) | 1997-04-15 | 2004-10-27 | Санкио Компани Лимитед | Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты) |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| AU2011202547B2 (en) * | 1997-04-16 | 2014-08-28 | Amgen Inc. | Osteoprotegerin binding proteins and receptors |
| EP1717315A3 (fr) * | 1997-04-16 | 2007-06-20 | Amgen Inc. | Protéines de liaison et récepteurs d'ostéoprotégérine |
| AU762574B2 (en) * | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
| CA2347107A1 (fr) | 1998-10-28 | 2000-05-04 | Shinichi Mochizuki | Agents therapeutiques pour deformations osseuses |
| AUPQ314799A0 (en) * | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| EP1257648B2 (fr) † | 2000-02-23 | 2016-09-14 | Amgen Inc. | Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine |
| WO2002024896A2 (fr) | 2000-09-22 | 2002-03-28 | Immunex Corporation | Methode de criblage d'agonistes ou d'antagonistes de l'activateur du recepteur de nf-kb |
| WO2002062990A1 (fr) * | 2001-02-07 | 2002-08-15 | Sankyo Company, Limited | Anticorps et utilisation de cet anticorps |
| WO2002079256A1 (fr) * | 2001-03-26 | 2002-10-10 | Sankyo Company, Limited | Anticorps et son utilisation |
| AU2002253133B2 (en) | 2001-04-03 | 2008-02-28 | Societe Des Produits Nestle S.A. | Osteoprotegerin in milk |
| TR201809008T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| EP1494714A4 (fr) | 2002-04-05 | 2008-03-05 | Amgen Inc | Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl |
| US7462700B2 (en) * | 2002-12-10 | 2008-12-09 | Schering-Plough Animal Health Corporation | Canine RANKL and methods for preparing and using the same |
| US20050009097A1 (en) * | 2003-03-31 | 2005-01-13 | Better Marc D. | Human engineered antibodies to Ep-CAM |
| AU2003282780A1 (en) | 2003-08-08 | 2005-03-07 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| US7318925B2 (en) | 2003-08-08 | 2008-01-15 | Amgen Fremont, Inc. | Methods of use for antibodies against parathyroid hormone |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2689328T3 (es) | 2004-01-07 | 2018-11-13 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpo monoclonal M-CSF-específico y usos del mismo |
| TWI359026B (en) * | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| US20070190560A1 (en) * | 2006-02-13 | 2007-08-16 | Olga Ornatsky | Element-tagged olignucleotide gene expression analysis |
| CA2651597C (fr) | 2006-05-12 | 2013-02-05 | Keio University | Detection d'une maladie inflammatoire et composition destinee a la prevention ou au traitement d'une maladie inflammatoire |
| EP2083073B1 (fr) | 2006-10-11 | 2013-09-04 | Oriental Yeast Co., Ltd. | Reactif contenant une proteine fusionnee de rankl soluble avec un marqueur d'epitope |
| WO2008044797A1 (fr) | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Animal modèle d'ostéopénie |
| WO2008044379A1 (fr) | 2006-10-11 | 2008-04-17 | Oriental Yeast Co., Ltd. | Modèle animal de perte osseuse |
| US20100260680A1 (en) | 2007-06-05 | 2010-10-14 | Oriental Yeast Co., Ltd. | Novel bone mass increasing agent |
| HUE025262T2 (en) | 2007-10-11 | 2016-02-29 | Daiichi Sankyo Co Ltd | Antibody targeting osteoclast-linked Siglec-15 protein |
| US8778359B2 (en) * | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| WO2010038610A1 (fr) | 2008-09-30 | 2010-04-08 | オリエンタル酵母工業株式会社 | Nouvel inducteur de la différenciation et de la prolifération de cellules de cartilage |
| CN102361632A (zh) * | 2009-03-30 | 2012-02-22 | 弗·哈夫曼-拉罗切有限公司 | 避免玻璃雾化的方法 |
| KR101690340B1 (ko) | 2009-04-09 | 2016-12-27 | 다이이찌 산쿄 가부시키가이샤 | 항 Ｓｉｇｌｅｃ-15 항체 |
| WO2011017294A1 (fr) * | 2009-08-07 | 2011-02-10 | Schering Corporation | Anticorps anti-rankl humain |
| EP2433644A1 (fr) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Traitement du cancer du sein |
| EP2434285A1 (fr) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Diagnostic du cancer du sein |
| MX2013003828A (es) | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos. |
| US20130280260A1 (en) * | 2010-10-13 | 2013-10-24 | Tokyo Women's Medical University | Osteoclastogenesis inhibitor containing anti-vdac antibody |
| CA2831247C (fr) | 2011-03-31 | 2020-07-21 | Oriental Yeast Co., Ltd. | Agent immunopotentialisant anticancereux contenant un antagoniste de rankl |
| JP6346602B2 (ja) * | 2012-03-21 | 2018-06-20 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ヒトリンパ器官由来の抑制性ストローマ細胞の単離および使用 |
| ES2660472T3 (es) | 2012-03-30 | 2018-03-22 | Daiichi Sankyo Company, Limited | Anticuerpo anti-Siglec-15 modificado con CDR |
| JP6268173B2 (ja) | 2012-07-19 | 2018-01-24 | 第一三共株式会社 | 抗Ｓｉｇｌｅｃ−１５抗体 |
| CN102788817B (zh) * | 2012-08-24 | 2015-04-08 | 中煤科工集团重庆研究院有限公司 | 超低温环境下可燃气体爆炸特性实验研究方法 |
| JP6599861B2 (ja) | 2013-08-07 | 2019-10-30 | リグスホスピタレット コペンハーゲン ユニバーシティ ホスピタル | 男性不妊治療用の抗体、化合物、およびその誘導体 |
| EP3086780A4 (fr) | 2013-12-27 | 2017-08-09 | Emergent Product Development Gaithersburg Inc. | Formulations de vaccin thermostables |
| KR101982782B1 (ko) * | 2016-09-13 | 2019-05-28 | 주식회사 이앤에스헬스케어 | 티오레독신 1에 특이적으로 결합하는 단일클론항체 및 이의 용도 |
| CN108410990B (zh) * | 2018-05-30 | 2021-07-06 | 中国医学科学院北京协和医院 | Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用 |
| CN112552382A (zh) * | 2020-01-22 | 2021-03-26 | 天津科技大学 | 一种信号肽突变体及其用途 |
| CN111333709B (zh) * | 2020-03-17 | 2023-09-08 | 吉林大学 | 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4710457A (en) * | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
| US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
| EP0192658A4 (fr) | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | Vecteurs retroviraux de transfert genetique. |
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
| US6027729A (en) * | 1989-04-20 | 2000-02-22 | Chiron Corporation | NANBV Diagnostics and vaccines |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| AU651421B2 (en) * | 1990-11-30 | 1994-07-21 | Celtrix Pharmaceuticals, Inc. | Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair |
| US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| CA2068389A1 (fr) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Methode d'inhibition de la resorption osseuse |
| MX9204303A (es) * | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
| IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
| CA2124967C (fr) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Animaux transgeniques non humains capables de produire des anticorps heterologues |
| US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| DK0639079T3 (da) | 1992-04-30 | 2000-06-13 | Amgen Inc | Fremgangsmåder til behandling af interleukin-1- og tumornekrosefaktor-medierede sygdomme |
| US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US5578569A (en) * | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
| US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| ATE202571T1 (de) | 1993-09-14 | 2001-07-15 | Merck & Co Inc | Humane protein-tyrosinphosphatase decodierende cdna |
| US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
| EP0727211A1 (fr) | 1995-02-10 | 1996-08-21 | Smithkline Beecham Corporation | Emploi de composés spécifiques src SH2 dans le traitement de maladies de résorption osseuse |
| IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| US7094564B1 (en) * | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| WO1996028546A1 (fr) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Recepteur humain du facteur de necrose tumorale |
| US20030166097A1 (en) * | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
| US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
| AU6090896A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
| WO1997000317A1 (fr) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Facteur regulateur de la croissance d'osteoclastes |
| US6369027B1 (en) * | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
| US5662948A (en) * | 1996-01-29 | 1997-09-02 | Chrysler Corporation | Adjustable and removable trimline inserts for a molding tool |
| US6750091B1 (en) * | 1996-03-01 | 2004-06-15 | Micron Technology | Diode formation method |
| JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規ｄｎａ及びそれを用いた蛋白質の製造方法 |
| EP1995318A1 (fr) * | 1996-12-13 | 2008-11-26 | Schering Corporation | Antigènes de surface de cellule de mammifère ; agents chimiques relatifs |
| FR2757507B1 (fr) | 1996-12-20 | 1999-01-29 | Inst Francais Du Petrole | Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation |
| WO1998028423A2 (fr) * | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions et procedes d'utilisation des facteurs inhibant les osteoclastes |
| JP2002509431A (ja) * | 1996-12-23 | 2002-03-26 | イミュネックス・コーポレーション | ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である− |
| US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
| RU2238949C2 (ru) | 1997-04-15 | 2004-10-27 | Санкио Компани Лимитед | Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты) |
| US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| EP1717315A3 (fr) * | 1997-04-16 | 2007-06-20 | Amgen Inc. | Protéines de liaison et récepteurs d'ostéoprotégérine |
| WO1998049305A1 (fr) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Polypeptides opg chimeres |
| AU7705098A (en) | 1997-05-29 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6087555A (en) * | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
| US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| AU762574B2 (en) | 1998-05-14 | 2003-06-26 | Immunex Corporation | Method of inhibiting osteoclast activity |
| AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
| US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
| ATE362374T1 (de) | 1999-09-03 | 2007-06-15 | Amgen Inc | Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust |
| US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
| TR201809008T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| EP1494714A4 (fr) * | 2002-04-05 | 2008-03-05 | Amgen Inc | Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl |
-
1998
- 1998-04-15 RU RU99100615/13A patent/RU2238949C2/ru active Protection Beyond IP Right Term
- 1998-04-15 EP EP98914034.8A patent/EP0911342B2/fr not_active Expired - Lifetime
- 1998-04-15 CA CA2257247A patent/CA2257247C/fr not_active Expired - Lifetime
- 1998-04-15 KR KR10-2003-7009671A patent/KR100496063B1/ko active Protection Beyond IP Right Term
- 1998-04-15 AU AU68518/98A patent/AU735355B2/en not_active Expired
- 1998-04-15 DK DK98914034.8T patent/DK0911342T4/da active
- 1998-04-15 CA CA2781623A patent/CA2781623A1/fr not_active Abandoned
- 1998-04-15 EP EP20100186133 patent/EP2336168A1/fr not_active Withdrawn
- 1998-04-15 DE DE122010000049C patent/DE122010000049I1/de active Pending
- 1998-04-15 ES ES98914034T patent/ES2263204T5/es not_active Expired - Lifetime
- 1998-04-15 IL IL127115A patent/IL127115A/en not_active IP Right Cessation
- 1998-04-15 JP JP54374198A patent/JP3523650B2/ja not_active Expired - Lifetime
- 1998-04-15 DE DE69834699T patent/DE69834699T3/de not_active Expired - Lifetime
- 1998-04-15 HU HU0800628A patent/HU229841B1/hu unknown
- 1998-04-15 AT AT98914034T patent/ATE328006T1/de active
- 1998-04-15 NZ NZ332995A patent/NZ332995A/xx not_active IP Right Cessation
- 1998-04-15 WO PCT/JP1998/001728 patent/WO1998046644A1/fr active IP Right Grant
- 1998-04-15 PT PT98914034T patent/PT911342E/pt unknown
- 1998-04-15 CN CNB988004771A patent/CN1138786C/zh not_active Expired - Lifetime
- 1998-04-15 HU HU0000717A patent/HU229476B1/hu active Protection Beyond IP Right Term
- 1998-04-15 EP EP05017241.0A patent/EP1657255B1/fr not_active Expired - Lifetime
- 1998-12-14 NO NO19985848A patent/NO322632B1/no not_active IP Right Cessation
-
2002
- 2002-06-11 US US10/167,182 patent/US7527790B2/en not_active Expired - Lifetime
-
2003
- 2003-06-13 JP JP2003169309A patent/JP3935861B2/ja not_active Expired - Lifetime
- 2003-06-13 US US10/460,623 patent/US7192718B2/en not_active Expired - Lifetime
-
2004
- 2004-05-27 US US10/854,300 patent/US7449185B2/en not_active Expired - Fee Related
- 2004-12-28 JP JP2004381995A patent/JP4230993B2/ja not_active Expired - Lifetime
-
2005
- 2005-05-24 US US11/135,521 patent/US20050208580A1/en not_active Abandoned
-
2006
- 2006-08-31 US US11/513,178 patent/US20080187540A9/en not_active Abandoned
-
2008
- 2008-07-25 JP JP2008191860A patent/JP4355357B2/ja not_active Expired - Lifetime
- 2008-10-07 JP JP2008260450A patent/JP4878616B2/ja not_active Expired - Lifetime
- 2008-12-19 US US12/340,327 patent/US20100136011A1/en not_active Abandoned
-
2010
- 2010-11-24 LU LU91759C patent/LU91759I2/fr unknown
- 2010-11-25 NO NO2010021C patent/NO2010021I2/no unknown
- 2010-11-25 FR FR10C0048C patent/FR10C0048I2/fr active Active
- 2010-11-30 CY CY2010017C patent/CY2010017I2/el unknown
-
2011
- 2011-09-08 JP JP2011195938A patent/JP5285751B2/ja not_active Expired - Lifetime
-
2012
- 2012-08-16 US US13/587,791 patent/US20120329671A1/en not_active Abandoned
-
2013
- 2013-03-13 JP JP2013050045A patent/JP5593407B2/ja not_active Expired - Lifetime
-
2014
- 2014-05-07 HU HUS1400027C patent/HUS1400027I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO322632B1 (no) | Anvendelse av et antistoff for fremstilling av et medikament til behandling av benmetabolismeunormalitet. | |
| AU781998B2 (en) | Receptor on the surface of activated T-cells: ACTS-4 | |
| AU2008200700C1 (en) | Novel Protein and Process for Producing The Same | |
| KR100436092B1 (ko) | 신규단백질및그제조방법 | |
| AU2014250718A1 (en) | Novel Protein and Process for Producing The Same | |
| AU2012204072A1 (en) | Novel Protein and Process for Producing The Same | |
| MXPA98010700A (en) | Novel protein and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: PROLIA; NAT. REG. NO/DATE: EU/1/10/618/001-4/NO 20100614; FIRST REG. NO/DATE: EU/1/10/618/001-004 20100526 Spc suppl protection certif: 2010021 Filing date: 20101125 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: PROLIA; NAT. REG. NO/DATE: EU/1/10/618/001-4/NO 20100614; FIRST REG. NO/DATE: EU/1/10/618/001-004 20100526 Spc suppl protection certif: 2010021 Filing date: 20101125 Extension date: 20230415 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2010021 Expiry date: 20230504 |